Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury : An international multi-centre observational cohort study
© 2022 Published by Elsevier Ltd..
Background: While acute kidney injury (AKI) is a common complication in COVID-19, data on post-AKI kidney function recovery and the clinical factors associated with poor kidney function recovery is lacking.
Methods: A retrospective multi-centre observational cohort study comprising 12,891 hospitalized patients aged 18 years or older with a diagnosis of SARS-CoV-2 infection confirmed by polymerase chain reaction from 1 January 2020 to 10 September 2020, and with at least one serum creatinine value 1-365 days prior to admission. Mortality and serum creatinine values were obtained up to 10 September 2021.
Findings: Advanced age (HR 2.77, 95%CI 2.53-3.04, p < 0.0001), severe COVID-19 (HR 2.91, 95%CI 2.03-4.17, p < 0.0001), severe AKI (KDIGO stage 3: HR 4.22, 95%CI 3.55-5.00, p < 0.0001), and ischemic heart disease (HR 1.26, 95%CI 1.14-1.39, p < 0.0001) were associated with worse mortality outcomes. AKI severity (KDIGO stage 3: HR 0.41, 95%CI 0.37-0.46, p < 0.0001) was associated with worse kidney function recovery, whereas remdesivir use (HR 1.34, 95%CI 1.17-1.54, p < 0.0001) was associated with better kidney function recovery. In a subset of patients without chronic kidney disease, advanced age (HR 1.38, 95%CI 1.20-1.58, p < 0.0001), male sex (HR 1.67, 95%CI 1.45-1.93, p < 0.0001), severe AKI (KDIGO stage 3: HR 11.68, 95%CI 9.80-13.91, p < 0.0001), and hypertension (HR 1.22, 95%CI 1.10-1.36, p = 0.0002) were associated with post-AKI kidney function impairment. Furthermore, patients with COVID-19-associated AKI had significant and persistent elevations of baseline serum creatinine 125% or more at 180 days (RR 1.49, 95%CI 1.32-1.67) and 365 days (RR 1.54, 95%CI 1.21-1.96) compared to COVID-19 patients with no AKI.
Interpretation: COVID-19-associated AKI was associated with higher mortality, and severe COVID-19-associated AKI was associated with worse long-term post-AKI kidney function recovery.
Funding: Authors are supported by various funders, with full details stated in the acknowledgement section.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
EClinicalMedicine - 55(2023) vom: 01. Jan., Seite 101724 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tan, Byorn W L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute kidney injury |
|---|
| Anmerkungen: |
Date Revised 20.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.eclinm.2022.101724 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348954123 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348954123 | ||
| 003 | DE-627 | ||
| 005 | 20240320232856.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eclinm.2022.101724 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM348954123 | ||
| 035 | |a (NLM)36381999 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tan, Byorn W L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury |b An international multi-centre observational cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 Published by Elsevier Ltd. | ||
| 520 | |a Background: While acute kidney injury (AKI) is a common complication in COVID-19, data on post-AKI kidney function recovery and the clinical factors associated with poor kidney function recovery is lacking | ||
| 520 | |a Methods: A retrospective multi-centre observational cohort study comprising 12,891 hospitalized patients aged 18 years or older with a diagnosis of SARS-CoV-2 infection confirmed by polymerase chain reaction from 1 January 2020 to 10 September 2020, and with at least one serum creatinine value 1-365 days prior to admission. Mortality and serum creatinine values were obtained up to 10 September 2021 | ||
| 520 | |a Findings: Advanced age (HR 2.77, 95%CI 2.53-3.04, p < 0.0001), severe COVID-19 (HR 2.91, 95%CI 2.03-4.17, p < 0.0001), severe AKI (KDIGO stage 3: HR 4.22, 95%CI 3.55-5.00, p < 0.0001), and ischemic heart disease (HR 1.26, 95%CI 1.14-1.39, p < 0.0001) were associated with worse mortality outcomes. AKI severity (KDIGO stage 3: HR 0.41, 95%CI 0.37-0.46, p < 0.0001) was associated with worse kidney function recovery, whereas remdesivir use (HR 1.34, 95%CI 1.17-1.54, p < 0.0001) was associated with better kidney function recovery. In a subset of patients without chronic kidney disease, advanced age (HR 1.38, 95%CI 1.20-1.58, p < 0.0001), male sex (HR 1.67, 95%CI 1.45-1.93, p < 0.0001), severe AKI (KDIGO stage 3: HR 11.68, 95%CI 9.80-13.91, p < 0.0001), and hypertension (HR 1.22, 95%CI 1.10-1.36, p = 0.0002) were associated with post-AKI kidney function impairment. Furthermore, patients with COVID-19-associated AKI had significant and persistent elevations of baseline serum creatinine 125% or more at 180 days (RR 1.49, 95%CI 1.32-1.67) and 365 days (RR 1.54, 95%CI 1.21-1.96) compared to COVID-19 patients with no AKI | ||
| 520 | |a Interpretation: COVID-19-associated AKI was associated with higher mortality, and severe COVID-19-associated AKI was associated with worse long-term post-AKI kidney function recovery | ||
| 520 | |a Funding: Authors are supported by various funders, with full details stated in the acknowledgement section | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute kidney injury | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Chronic kidney disease | |
| 650 | 4 | |a Electronic health records | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Tan, Bryce W Q |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Amelia L M |e verfasserin |4 aut | |
| 700 | 1 | |a Schriver, Emily R |e verfasserin |4 aut | |
| 700 | 1 | |a Gutiérrez-Sacristán, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Priyam |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, William |e verfasserin |4 aut | |
| 700 | 1 | |a Hutch, Meghan R |e verfasserin |4 aut | |
| 700 | 1 | |a García Barrio, Noelia |e verfasserin |4 aut | |
| 700 | 1 | |a Pedrera Jimenez, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Abu-El-Rub, Noor |e verfasserin |4 aut | |
| 700 | 1 | |a Morris, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Moal, Bertrand |e verfasserin |4 aut | |
| 700 | 1 | |a Verdy, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Kelly |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Yuk-Lam |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Lav P |e verfasserin |4 aut | |
| 700 | 1 | |a Dagliati, Arianna |e verfasserin |4 aut | |
| 700 | 1 | |a Neuraz, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Klann, Jeffrey G |e verfasserin |4 aut | |
| 700 | 1 | |a South, Andrew M |e verfasserin |4 aut | |
| 700 | 1 | |a Visweswaran, Shyam |e verfasserin |4 aut | |
| 700 | 1 | |a Hanauer, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Maidlow, Sarah E |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Mei |e verfasserin |4 aut | |
| 700 | 1 | |a Mowery, Danielle L |e verfasserin |4 aut | |
| 700 | 1 | |a Batugo, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Makoudjou, Adeline |e verfasserin |4 aut | |
| 700 | 1 | |a Tippmann, Patric |e verfasserin |4 aut | |
| 700 | 1 | |a Zöller, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Brat, Gabriel A |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Avillach, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Bellazzi, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Chiovato, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Malovini, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Tibollo, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Samayamuthu, Malarkodi Jebathilagam |e verfasserin |4 aut | |
| 700 | 1 | |a Serrano Balazote, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Zongqi |e verfasserin |4 aut | |
| 700 | 1 | |a Loh, Ne Hooi Will |e verfasserin |4 aut | |
| 700 | 1 | |a Chiudinelli, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Bonzel, Clara-Lea |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Chuan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Harrison G |e verfasserin |4 aut | |
| 700 | 1 | |a Weber, Griffin M |e verfasserin |4 aut | |
| 700 | 1 | |a Kohane, Isaac S |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Tianxi |e verfasserin |4 aut | |
| 700 | 1 | |a Omenn, Gilbert S |e verfasserin |4 aut | |
| 700 | 1 | |a Holmes, John H |e verfasserin |4 aut | |
| 700 | 1 | |a Ngiam, Kee Yuan |e verfasserin |4 aut | |
| 700 | 0 | |a Consortium for Clinical Characterization of COVID-19 by EHR (4CE) |e verfasserin |4 aut | |
| 700 | 1 | |a Aaron, James R |e investigator |4 oth | |
| 700 | 1 | |a Agapito, Giuseppe |e investigator |4 oth | |
| 700 | 1 | |a Albayrak, Adem |e investigator |4 oth | |
| 700 | 1 | |a Albi, Giuseppe |e investigator |4 oth | |
| 700 | 1 | |a Alessiani, Mario |e investigator |4 oth | |
| 700 | 1 | |a Alloni, Anna |e investigator |4 oth | |
| 700 | 1 | |a Amendola, Danilo F |e investigator |4 oth | |
| 700 | 1 | |a Angoulvant, François |e investigator |4 oth | |
| 700 | 1 | |a Anthony, Li Llj |e investigator |4 oth | |
| 700 | 1 | |a Aronow, Bruce J |e investigator |4 oth | |
| 700 | 1 | |a Ashraf, Fatima |e investigator |4 oth | |
| 700 | 1 | |a Atz, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Avillach, Paul |e investigator |4 oth | |
| 700 | 1 | |a Panickan, Vidul Ayakulangara |e investigator |4 oth | |
| 700 | 1 | |a Azevedo, Paula S |e investigator |4 oth | |
| 700 | 1 | |a Balshi, James |e investigator |4 oth | |
| 700 | 1 | |a Batugo, Ashley |e investigator |4 oth | |
| 700 | 1 | |a Beaulieu-Jones, Brett K |e investigator |4 oth | |
| 700 | 1 | |a Beaulieu-Jones, Brendin R |e investigator |4 oth | |
| 700 | 1 | |a Bell, Douglas S |e investigator |4 oth | |
| 700 | 1 | |a Bellasi, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Bellazzi, Riccardo |e investigator |4 oth | |
| 700 | 1 | |a Benoit, Vincent |e investigator |4 oth | |
| 700 | 1 | |a Beraghi, Michele |e investigator |4 oth | |
| 700 | 1 | |a Bernal-Sobrino, José Luis |e investigator |4 oth | |
| 700 | 1 | |a Bernaux, Mélodie |e investigator |4 oth | |
| 700 | 1 | |a Bey, Romain |e investigator |4 oth | |
| 700 | 1 | |a Bhatnagar, Surbhi |e investigator |4 oth | |
| 700 | 1 | |a Blanco-Martínez, Alvar |e investigator |4 oth | |
| 700 | 1 | |a Boeker, Martin |e investigator |4 oth | |
| 700 | 1 | |a Bonzel, Clara-Lea |e investigator |4 oth | |
| 700 | 1 | |a Booth, John |e investigator |4 oth | |
| 700 | 1 | |a Bosari, Silvano |e investigator |4 oth | |
| 700 | 1 | |a Bourgeois, Florence T |e investigator |4 oth | |
| 700 | 1 | |a Bradford, Robert L |e investigator |4 oth | |
| 700 | 1 | |a Brat, Gabriel A |e investigator |4 oth | |
| 700 | 1 | |a Bréant, Stéphane |e investigator |4 oth | |
| 700 | 1 | |a Brown, Nicholas W |e investigator |4 oth | |
| 700 | 1 | |a Bruno, Raffaele |e investigator |4 oth | |
| 700 | 1 | |a Bryant, William A |e investigator |4 oth | |
| 700 | 1 | |a Bucalo, Mauro |e investigator |4 oth | |
| 700 | 1 | |a Bucholz, Emily |e investigator |4 oth | |
| 700 | 1 | |a Burgun, Anita |e investigator |4 oth | |
| 700 | 1 | |a Cai, Tianxi |e investigator |4 oth | |
| 700 | 1 | |a Cannataro, Mario |e investigator |4 oth | |
| 700 | 1 | |a Carmona, Aldo |e investigator |4 oth | |
| 700 | 1 | |a Cattelan, Anna Maria |e investigator |4 oth | |
| 700 | 1 | |a Caucheteux, Charlotte |e investigator |4 oth | |
| 700 | 1 | |a Champ, Julien |e investigator |4 oth | |
| 700 | 1 | |a Chen, Jin |e investigator |4 oth | |
| 700 | 1 | |a Chen, Krista Y |e investigator |4 oth | |
| 700 | 1 | |a Chiovato, Luca |e investigator |4 oth | |
| 700 | 1 | |a Chiudinelli, Lorenzo |e investigator |4 oth | |
| 700 | 1 | |a Cho, Kelly |e investigator |4 oth | |
| 700 | 1 | |a Cimino, James J |e investigator |4 oth | |
| 700 | 1 | |a Colicchio, Tiago K |e investigator |4 oth | |
| 700 | 1 | |a Cormont, Sylvie |e investigator |4 oth | |
| 700 | 1 | |a Cossin, Sébastien |e investigator |4 oth | |
| 700 | 1 | |a Craig, Jean B |e investigator |4 oth | |
| 700 | 1 | |a Cruz-Bermúdez, Juan Luis |e investigator |4 oth | |
| 700 | 1 | |a Cruz-Rojo, Jaime |e investigator |4 oth | |
| 700 | 1 | |a Dagliati, Arianna |e investigator |4 oth | |
| 700 | 1 | |a Daniar, Mohamad |e investigator |4 oth | |
| 700 | 1 | |a Daniel, Christel |e investigator |4 oth | |
| 700 | 1 | |a Das, Priyam |e investigator |4 oth | |
| 700 | 1 | |a Devkota, Batsal |e investigator |4 oth | |
| 700 | 1 | |a Dionne, Audrey |e investigator |4 oth | |
| 700 | 1 | |a Duan, Rui |e investigator |4 oth | |
| 700 | 1 | |a Dubiel, Julien |e investigator |4 oth | |
| 700 | 1 | |a DuVall, Scott L |e investigator |4 oth | |
| 700 | 1 | |a Esteve, Loic |e investigator |4 oth | |
| 700 | 1 | |a Estiri, Hossein |e investigator |4 oth | |
| 700 | 1 | |a Fan, Shirley |e investigator |4 oth | |
| 700 | 1 | |a Follett, Robert W |e investigator |4 oth | |
| 700 | 1 | |a Ganslandt, Thomas |e investigator |4 oth | |
| 700 | 1 | |a García-Barrio, Noelia |e investigator |4 oth | |
| 700 | 1 | |a Garmire, Lana X |e investigator |4 oth | |
| 700 | 1 | |a Gehlenborg, Nils |e investigator |4 oth | |
| 700 | 1 | |a Getzen, Emily J |e investigator |4 oth | |
| 700 | 1 | |a Geva, Alon |e investigator |4 oth | |
| 700 | 1 | |a González, Tomás González |e investigator |4 oth | |
| 700 | 1 | |a Gradinger, Tobias |e investigator |4 oth | |
| 700 | 1 | |a Gramfort, Alexandre |e investigator |4 oth | |
| 700 | 1 | |a Griffier, Romain |e investigator |4 oth | |
| 700 | 1 | |a Griffon, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Grisel, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Gutiérrez-Sacristán, Alba |e investigator |4 oth | |
| 700 | 1 | |a Guzzi, Pietro H |e investigator |4 oth | |
| 700 | 1 | |a Han, Larry |e investigator |4 oth | |
| 700 | 1 | |a Hanauer, David A |e investigator |4 oth | |
| 700 | 1 | |a Haverkamp, Christian |e investigator |4 oth | |
| 700 | 1 | |a Hazard, Derek Y |e investigator |4 oth | |
| 700 | 1 | |a He, Bing |e investigator |4 oth | |
| 700 | 1 | |a Henderson, Darren W |e investigator |4 oth | |
| 700 | 1 | |a Hilka, Martin |e investigator |4 oth | |
| 700 | 1 | |a Ho, Yuk-Lam |e investigator |4 oth | |
| 700 | 1 | |a Holmes, John H |e investigator |4 oth | |
| 700 | 1 | |a Honerlaw, Jacqueline P |e investigator |4 oth | |
| 700 | 1 | |a Hong, Chuan |e investigator |4 oth | |
| 700 | 1 | |a Huling, Kenneth M |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t EClinicalMedicine |d 2018 |g 55(2023) vom: 01. Jan., Seite 101724 |w (DE-627)NLM289300495 |x 2589-5370 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2023 |g day:01 |g month:01 |g pages:101724 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.eclinm.2022.101724 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2023 |b 01 |c 01 |h 101724 | ||